|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||111.04|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HENDERSON, NV / ACCESSWIRE / September 18, 2018 / A very interesting biotech firm DCTH (Delcath Systems, Inc.), has an intriguing treatment for liver cancer. The company has initiated a global Phase 3 ...
This prediction doesn't require Nostradamus: The marijuana bubble will pop at some point in the not-too-distant future.
LEAMINGTON, ON, Sept. 14, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that Dennis Staudt has resigned from the Company's Board of Directors (the "Board"). Mr. Staudt served as Lead Independent Director and Chair of the Audit Committee, and he had been a member of the Board since 2014, before the company was publicly traded.
HENDERSON, NV/ ACCESSWIRE / September 14, 2018 / A fascinating biotech firm DCTH (Delcath Systems, Inc.), has a very intriguing treatment for liver cancer. The company has initiated a global Phase 3 clinical ...
On September 11, CannTrust Holdings (CNTTF) received a favorable report from Canaccord Genuity, which raised the company’s price target from 13 Canadian dollars to 14.5 Canadian dollars. This price target was almost 57% higher than the stock’s closing price of 9.2 Canadian dollars on the day. The overall consensus recommendation for CannTrust is a “buy,” which was unchanged from last month. In the current month, three analysts maintained a “strong buy” recommendation on the stock, while five analysts had a “buy” recommendation on the company.
Aphria (APHQF) has heavily focused on the medical cannabis market and continues to do so as we move towards the planned legalization of recreational cannabis in Canada on October 17, 2018. The company has supply agreements with Canadian provinces to supply cannabis for recreational purposes. To learn more about the product strategy of cannabis players (HMLSF) such as Canopy Growth (CGC) (WEED) and Aurora Cannabis (ACB)(ACBFF), read Finding the Right Cannabis Stock for Your Portfolio.
Canopy Growth (CGC) (WEED) is one of the top cannabis stocks (MJ) in terms of market capitalization followed by Aurora Cannabis (ACB) (ACBFF) and Aphria (APHQF). On September 5, Canopy Growth received a price target upgrade from Cowen and Company from 56 Canadian dollars to 74 Canadian dollars.
Canada in particular is the focus as of late with a number of Canadian cannabis stocks benefiting in a big way from new highs in the market. According to estimates by cannabis researchers at ArcView Market Research in partnership with BDS Analytics, the latest revenue projections for the U.S. medical cannabis industry in 2018 is $4.3 billion versus $6.7 billion for adult use. Last year, medical marijuana sales came in just under $6 billion while adult use grabbed $2.6 billion.
Despite Health Canada issuing 116 licenses through August, a small handful of growers could combine for more than 1.5 million kilograms of annual production.
LEAMINGTON, ON, Sept. 12, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a wholesale supply agreement with Emblem Cannabis Corp., wholly owned subsidiary of Emblem Corp. and a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("Emblem") to supply 175,000 kg of high-quality cannabis over a five-year period starting May 2019 (the "Agreement") with a total of 25,000 kg deliverable for the balance of the first year. Under the terms of the Agreement, Aphria will receive a non-refundable deposit of $22.8 million, which is comprised of $12.8 million in cash, and 6,952,169 of common shares of Emblem. "Aphria's total annualized production capabilities are about to reach 255,000kg in early 2019, which means we are not only well positioned to meet all of our supply commitments across Canada and anticipated international demand, but also have the capacity to support the projected demand through our partners," said Gregg Battersby, Vice President of Commercial Strategy at Aphria.
HENDERSON, NV / ACCESSWIRE / September 11, 2018 / A very interesting biotechnology company ENDV (Endonovo Therapeutics, Inc.), has an FDA cleared product, and is flying under the radar. ENDV has been on ...
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...
The legalization of cannabis is taking hold on a global scale and even CEO's like Tesla's (TSLA) Elon Musk appear to be taking a liking to new legislation. Investors are now looking to Canadian marijuana stocks as these have continued to reach new milestones over recent months. With the industry expecting continued to grow after Oct. 17, when weed will become legal across Canada for any purpose, a number of investors are looking to get a piece of the action.
A product differentiation strategy, as the name suggests, entails the creation of unique products that can command higher prices, which, in turn, can result in higher margins. Product differentiation appears to be the primary strategic direction for most cannabis players to blanket the market with several products. Aphria also announced that it will list about 59 SKUs on Ontario’s online store.
Why fighting off black market demand for cannabis may not be as easy as it sounds for companies like Aphria Inc. (TSX:APH), Cronos Group Inc (TSX:CRON)(NASDAQ:CRON), and Tilray Inc. (NASDAQ:TLRY).
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / U.S. benchmarks closed mostly lower on Thursday, with the Dow Jones remaining in the green, as internet and tech shares slumped. The Dow Jones Industrial Average was up 0.08 percent to close at 25,995.87, while the S&P 500 Index decreased 0.37 percent to close at 2,878.05. According to Peter Kenny, market strategist at Kenny & Co, “This is very much a tech-centric reversion.
HENDERSON NV / ACCESSWIRE / September 6, 2018 / Metastatic liver disease is one of the most common causes of death in cancer patients. Complete surgical resection is currently considered the only curative ...
LEAMINGTON, ON, Sept. 6, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a share purchase agreement with a group of buyers, each acting individually and not in concert, including a member of the Serruya family, and has completed the sale of 64,118,462 shares (the "Shares") in Liberty Health Sciences, Inc. ("Liberty"), representing 100% of the Company's outstanding investment in Liberty. As part of the transaction, Aphria retains an irrevocable option to repurchase the Shares or any replacement securities from the buyers for a period of up to five years, subject to the satisfaction of certain conditions as further described below.
HENDERSON, NV / ACCESSWIRE / August 30, 2018 / A technology firm that we have discovered is APTY (APT Systems, Inc.). APTY is a tech firm based out of San Francisco, CA. APTY has been receiving increased ...
During the second quarter, Tilray’s (TLRY) adjusted EBITDA was -$4.7 million—compared to -$1.9 million in the second quarter of 2017. The company reported a net loss, which widened to $12.8 million from $2.4 million in the second quarter of 2017.
Tilray’s (TLRY) average selling prices and sales volume improved year-over-year in the second quarter. Looking at the sales volume, there was an overall increase, which indicates an increased uptake in the demand for Tilray’s products. The growth in average selling prices was driven by “higher potency products and extract sales” according to the company.
HENDERSON, NV / ACCESSWIRE / August 28, 2018 / This summer has been a great one for cannabis and biotech stocks. Usually summers are pretty quiet, but with Constellation Brands investing $4 Billion dollars ...